Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Radiation Therapy in Locoregional Pancreatic Cancer
NCT00003546Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 1998
- Primary completion
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Primary endpoints: Time to Progression up to 3 years and Overall Survival up to 3 years. Started Sep 1998; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00003546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003546.